BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals discovers, develops, and commercializes therapies targeting rare diseases and acute medical conditions. The company's lead commercial product, ORLADEYO, is an oral, once-daily therapy approved for the prevention of hereditary angioedema attacks in adult and pediatric patients. Its commercial portfolio also includes RAPIVAB, an intravenous neuraminidase inhibitor approved for the treatment of acute uncomplicated influenza. Additionally, the company advances a clinical pipeline of small-molecule and protein drug candidates for indications such as Netherton syndrome, diabetic macular edema, and atopic dermatitis. BioCryst distributes its therapies to patients through specialty pharmacy providers and collaborates with government bodies, commercial licensees, and healthcare distributors to supply medicines to global healthcare systems.

BioCryst maintains commercial teams and partnerships across international markets, including the United States, Japan, Australia, Canada, Korea, and Latin America. Its European ORLADEYO business was transferred to a regional commercial partner. The provided text does not state the location of the company's headquarters.

Summary of the business section of Biocryst Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 435 employees, of whom approximately 118 employees were engaged in the research and development function of our operations, which we define to include any employee included in research and development expenses for financial reporting purposes.”